In last trading session, Neurogene Inc (NASDAQ:NGNE) saw 0.34 million shares changing hands with its beta currently measuring 1.64. Company’s recent per share price level of $8.79 trading at -$0.88 or -9.10% at ring of the bell on the day assigns it a market valuation of $131.23M. That closing price of NGNE’s stock is at a discount of -747.44% from its 52-week high price of $74.49 and is indicating a discount of -4.89% from its 52-week low price of $9.22. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.33 million shares which gives us an average trading volume of 243.87K if we extend that period to 3-months.
For Neurogene Inc (NGNE), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.14. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.92 in the current quarter.
Neurogene Inc (NASDAQ:NGNE) trade information
Upright in the red during last session for losing -9.10%, in the last five days NGNE remained trading in the red while hitting it’s week-highest on Monday, 03/31/25 when the stock touched $8.79 price level, adding 36.44% to its value on the day. Neurogene Inc’s shares saw a change of -61.55% in year-to-date performance and have moved -39.46% in past 5-day. Neurogene Inc (NASDAQ:NGNE) showed a performance of -47.52% in past 30-days. Number of shares sold short was 2.18 million shares which calculate 12.51 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 46 to the stock, which implies a rise of 80.89% to its current value. Analysts have been projecting 45 as a low price target for the stock while placing it at a high target of 50. It follows that stock’s current price would drop -411.95% in reaching the projected high whereas dropping to the targeted low would mean a loss of -411.95% for stock’s current value.
Neurogene Inc (NGNE) estimates and forecasts
This year revenue growth is estimated to fall -100.00% from the last financial year’s standing.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -10.74% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -7.96% while estimates for its earnings growth in next 5 years are of -8.29%.
Neurogene Inc (NASDAQ:NGNE)’s Major holders
Insiders are in possession of 10.16% of company’s total shares while institution are holding 108.36 percent of that, with stock having share float percentage of 120.60%. Investors also watch the number of corporate investors in a company very closely, which is 108.36% institutions for Neurogene Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at NGNE for having 1.39 million shares of worth $50.75 million. And as of 2024-06-30, it was holding 8.2325 of the company’s outstanding shares.
The second largest institutional holder is ECOR1 CAPITAL, LLC, which was holding about 1.27 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.5043 of outstanding shares, having a total worth of $46.26 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Securities Fund-Fidelity Small Cap Growth Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 327.17 shares of worth $2.88 million or 2.19% of the total outstanding shares. The later fund manager was in possession of 288.92 shares on Jan 31, 2025 , making its stake of worth around $2.54 million in the company or a holder of 1.94% of company’s stock.
